Recursion Pharmaceuticals (RXRX) AI Stock Analysis

The financial profile reflects an early-stage, unprofitable biotech/AI-drug discovery company with negative earnings and no clear line of sight to near‑term profitability. A negative EPS of -1.16 and a negative PE ratio of -2.78 indicate ongoing losses and a valuation that is not supported by current earnings power.

• Negative EPS (-1.16) and a negative PE ratio (-2.78) confirm that Recursion is loss‑making and investors are effectively paying for future optionality rather than current profits.
• The lack of profitability implies weak or negative net income and pressure on profitability ratios (net margin, return on equity, return on assets), which are likely deeply negative.
• Given the business model (R&D‑heavy biotech/tech hybrid), cash burn and dependence on external financing or partnership funding remain key risks for equity holders until there is clearer revenue and earnings traction.

Despite a modest 3.9% gain over the last month, the stock trades at $3.23, well below its 200‑day moving average of $4.16, indicating a longer‑term downtrend. The price action suggests recent stabilization or a short‑term bounce within a broader bearish technical setup.

• Current price of $3.23 is materially under the 200‑day moving average of $4.16, a classic sign of a prevailing downward trend and longer‑term technical weakness.
• The 3.9% one‑month increase is positive but modest, and does not yet signal a confirmed trend reversal; it could represent a mean‑reversion bounce or short‑covering rally.
• With negative earnings and no PE-based valuation support, the stock’s technicals are likely to be more sentiment‑driven and volatile, and remaining below the 200‑day average keeps the technical picture skewed to the downside.

Overall, Recursion Pharmaceuticals’ stock profile is tilted bearish: the company remains unprofitable with negative earnings, and the share price trades well below its 200‑day moving average despite a small recent bounce. Alternative data are broadly stable but not strong enough to offset the financial and technical headwinds at this stage.

• Persistent losses and a negative PE ratio, combined with a share price below the 200‑day moving average, indicate that the equity story is still highly speculative and vulnerable to downside if expectations are not met.
• Alternative data show only moderate engagement and a slowdown in hiring, which supports a cautious stance until there is clearer evidence of accelerating business traction or a sustained technical trend reversal.